ESTRO 2024 - Abstract Book

S256

Brachytherapy - Gynaecology

ESTRO 2024

Conclusion:

Moderate positive correlation alone could be established between the recommended upper vaginal dose points and vaginal DV parameters. The search to identify better parameters to predict doses to vagina must continue.

Keywords: Vaginal Dose Points, ICBT, Carcinoma Cervix

References:

1. Westervald H et al. Multicentre evaluation of a novel vaginal dose reporting method in 153 cervical cancer patients. Radiother Oncol. 2016 Sep; 120(3):420-427

2. Bajwa HK et al, Comparison of dose delivered to vagina using two different intracavitary apllicators for Carcinoma Cervix Brachytherapy. 2022 Mar-April; 21(2): 151-157

3. Westerveld H,et al. Vaginal dose point reporting in cervical cancer patients treated with combined 2D/3D external beam radiotherapy and 2D/3D brachytherapy. Radiother Oncol. 2013 Apr;107(1):99-105.

4.Limkin EJ et al. Vaginal dose assessment in image-guided brachytherapy for cervical cancer: Can we really rely on dose-point evaluation? Brachytherapy. 2016 Mar-Apr;15(2):169-76.

1693

Proffered Paper

Real-world clinical outcome from using the EMBRACE-II protocol in locally advanced cervical cancer

Jacob Chr. Lindegaard 1 , Christian Kirisits 2 , Maximilian Paul Schmid 2 , Christian Nielsen Wulff 1 , Sarah Grønbech Steen 1 , Kristina Bak Kristoffersen 1 , Richard Pötter 2 , Primoz Petric 3 1 Aarhus University Hospital, Department of Oncology, Aarhus, Denmark. 2 Comprehensive Cancer Center, Medical University of Vienna, Department of Radiation Oncology, Vienna, Austria. 3 University Hospital Zürich, Department of Radiation Oncology, Zürich, Switzerland

Purpose/Objective:

The EMBRACE-I study on MRI guided adaptive brachytherapy (IGABT) in locally advanced cervical cancer demonstrated that certain dose-volume planning aims for the combined dose of external beam radiotherapy (EBRT) and IGABT should be enforced to optimize the clinical outcome [Pötter 2021]. In 2016-2021 these state-of the-art principles were applied in the multicentre EMBRACE-II study [Pötter 2018]. Results of EMBRACE-II is still pending. Although the inclusion criteria for the EMBRACE studies were quite generous it is possible that selection bias was present as evidenced by a high rate of concomitant chemotherapy. The aim of the present study was to analyse real-world clinical outcome of EBRT and IGABT performed according to EMBRACE-II in a consecutive cohort including both patients included and not included in EMBRACE and to assess impact of this selection with regard to patient characteristics, treatment parameters and clinical outcome.

Material/Methods: